-transparent.png){kind=logo}
A conceptual breakthrough in gene therapy would be gene transfer vector that could be systemically applied, allowing targeted gene transfer into a predetermined cell type. The host range of a retroviral vector is determined by the interaction of the viral envelope glycoprotein (Env) and the retrovirus receptor on the surface of the host cell. In this review, we describe the current efforts to engineer targeted envelope glycoproteins, which can be incorporated into retroviral particles and are capable of delivering genes in a highly specific manner.
Related Publications
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
January 2015,
Progress in molecular biology and translational science,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
June 1990,
AIDS research and human retroviruses,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
December 1991,
The Journal of biological chemistry,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
February 2004,
Journal of virology,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
January 2017,
Small GTPases,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
May 2020,
PLoS pathogens,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
January 2009,
Methods in molecular biology (Clifton, N.J.),
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
August 2001,
Molecular therapy : the journal of the American Society of Gene Therapy,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
October 1993,
AIDS research and human retroviruses,
Catherine Haynes, and
Otto Erlwein, and
Barbara S Schnierle
January 1994,
Revue roumaine de virologie (Bucharest, Romania : 1990),
